ProKidney Corp. (PROK)
| Previous Close | 2.3900 |
| Open | 2.3900 |
| Bid | 2.2500 x 100 |
| Ask | 2.2700 x 100 |
| Day's Range | 2.2200 - 2.3900 |
| 52 Week Range | 1.1200 - 9.2500 |
| Volume | |
| Avg. Volume | 727,649 |
| Market Cap | 1.702B |
| Beta (5Y Monthly) | 1.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6000 |
| Earnings Date | Aug 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.67 |
GlobeNewswireProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Morgan Stanley 22nd Annual Global Healthcare Conference, being held in New York, NY on September 4-6, 2024. Morgan Stanley 22nd Annual Global Healthcare Conferen
- GlobeNewswire
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
Reported interim REGEN-007 data that demonstrate rilparencel’s potential to preserve kidney function in patients with diabetes and advanced CKDRestarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trialsClosed $140 million upsized underwritten public offering and concurrent registered direct offeringEnded the second quarter with $431.5 million in cash and cash equivalents and marketable securities, supporting operations through projected Phase 3 enrollment completion in mid-2026 WINS
Simply Wall St.ProKidney Corp.'s (NASDAQ:PROK) top owners are retail investors with 32% stake, while 30% is held by institutions
Key Insights Significant control over ProKidney by retail investors implies that the general public has more power to...
